Literature DB >> 212382

Influences on the density of beta-adrenergic receptors in the cornea and iris--ciliary body of the rabbit.

A H Neufeld, K A Zawistowski, E D Page, B B Bromberg.   

Abstract

By measurement of the specific binding of 3H-dihydroalprenolol, the densities of beta-adrenergic receptors on membranes prepared from homogenized corneas and iris--ciliary bodies of rabbits were studied. Sympathetic denervation, as a result of subconjunctival treatment with 6-hydroxydopamine, causes an increase in the density of beta-adrenergic receptors in membranes prepared from the ipsilateral iris--ciliary body but not the cornea. Topical treatment with epinephrine for 5 days causes a decrease in the density of beta-adrenergic receptors in membranes prepared from cornea and iris-ciliary body, whereas similar treatment with timolol causes an increase in the density of beta-adrenergic receptors. In the cornea, the decrease in receptor density that occurs following in vivo treatment with epinephrine is associated with a decreased ability to synthesize cyclic AMP, whereas the increase in receptor density that occurs following in vivo treatment with timolol is not associated with an altered ability to synthesize cyclic AMP. Our results indicate that the density of beta-adrenergic receptors in the anterior segment of the eye is inversely related to the level of adrenergic stimulation to the tissue but that the ability of a tissue to synthesize cyclic AMP does not necessarily parallel the change in receptor density.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212382

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Blind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma.

Authors:  K B Mills
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

2.  Interaction of timolol and adrenaline.

Authors:  A Ohrström; O Kättström
Journal:  Br J Ophthalmol       Date:  1981-01       Impact factor: 4.638

3.  [The effect of timolol and dipivalyl-epinephrine in the treatment of the elevated intraocular pressure (author's transl)].

Authors:  M Ober; A Scharrer
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1980

4.  Diurnal rhythm of mitosis in rabbit corneal epithelium.

Authors:  J A Fogle; B K Yoza; A H Neufeld
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1980

5.  Effect of Timolol on Aqueous Humor Outflow Facility in Healthy Human Eyes.

Authors:  Arash Kazemi; Jay W McLaren; Matthew G J Trese; Carol B Toris; Vikas Gulati; Shan Fan; David M Reed; Tyler Kristoff; Jesse Gilbert; Sayoko E Moroi; Arthur J Sit
Journal:  Am J Ophthalmol       Date:  2019-02-19       Impact factor: 5.258

6.  Dose-related interaction between timolol and adrenaline.

Authors:  A Ohrström
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

7.  Short-term and long-term timolol maleate effects on corneal sensitivity.

Authors:  D Spinelli; F Vigasio; P Montanari
Journal:  Doc Ophthalmol       Date:  1984-02-29       Impact factor: 2.379

8.  Long-term drift and timolol therapy: possible role for pulsed therapy.

Authors:  M Batterbury; S P Harding; D Wong
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

9.  Nerve terminal degeneration in the rat iris observed following chronic topical 2% epinephrine and 0.1% dipivalyl epinephrine: a quantitative comparison of electron microscopic observations and tissue norepinephrine levels.

Authors:  A J Flach; M E Donahue; I S Wood
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

10.  A single-blind randomised trial comparing adrenaline 1.0% with dipivalyl epinephrine (propine) 0.1% in the treatment of open-angle glaucoma and ocular hypertension.

Authors:  K B Mills; N A Jacobs
Journal:  Br J Ophthalmol       Date:  1988-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.